Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome
MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with ...
The Scientist11h
Stem Cell Discovery in Human Retina May Lead to Retinal Degeneration Treatments
Stem cell therapies hold promise for promoting regeneration. Retinal stem cells (RSCs) possess self-renewal capabilities and ...
SLU student hosts blood stem cell donor drive to save lives
A Saint Louis University student is making a significant impact by organizing a blood stem cell donor registration drive on ...
BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
Conference call and webcast at 8:30 a.m. Eastern Time today NEW YORK, March 31, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading ...
Vertex Pharmaceuticals pursuing research-stage T1Dd programs
Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...
Single-cell Analysis Market Surges to USD 5.4 Billion by 2033, Propelled by 9.5% CAGR - Verified Market Reports®
The Global Single-cell Analysis Market is projected to grow at a CAGR of 9.5% from 2026 to 2033, according to a new report ...
Cell & Gene Therapies in Gastrointestinal Disorders Therapeutic Analysis Report 2024: Sales are Forecast to Reach $187 Million by 2030
The "Cell & Gene Therapies in Gastrointestinal Disorders: Therapeutic Analysis" report has been added to ResearchAndMarkets.com's offering.Both marketed therapies are prescribed when a patient has ...
CAR T-Cell Therapy Market Size To Reach 27.5 Billion by 2033 Owing to Rising Awareness and Favourable Reimbursement Policies Says Astute Analytica
The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.
Mitsubishi Tanabe Pharma America Announces Publication of Preclinical Research on the Role of Edaravone in Mitigating TDP-43 Mislocalization in ALS
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of new preclinical research in Free Radical Biology and Medicine, highlighting the role of edaravone in mitigating TDP-43 ...
The Jewish Press10d
TAU Breakthrough: Doubling Adult Stem Cells Outside the Body to Regenerate Bone Marrow
Activating stem cells via molecular programming, rather than relying on random cell transplants, significantly enhances the success of regenerative treatments.